MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    DBS Targeting in a Neuromodulation Monitoring Unit – First 30 cases

    T. Sanger, J. Maclean, A. Tongol, J. Olaya, M. Liker (Orange, USA)

    Objective: We evaluate potential targets for Deep Brain Stimulation (DBS) based on test stimulation and chronic recording from temporary depth electrodes placed in a Neuromodulation Monitoring…
  • 2022 International Congress

    Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG

    T. Gurevich, A. Evans, G. Kägi, D. Koziorowksi, L. Bergmann, JC. Parra Riaza, O. Sanchez-Soliño, J. Slawek (Tel Aviv, Israel)

    Objective: To evaluate the feasibility and patient satisfaction of video-assisted telenursing as well as demonstrate resolution for treatment-related issues in the real-word levodopa-carbidopa intestinal gel…
  • 2022 International Congress

    Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…
  • 2022 International Congress

    Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

    GL. Ndji Otto, H. Adjia, JP. Mingoas Kilekoung (Bertoua, Cameroon)

    Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…
  • 2022 International Congress

    Neuropathological profile of tauopathy in spinocerebellar ataxia type 8

    G. Beck, Y. Yonenobu, R. Yamashita, T. Iwaki, S. Murayama, H. Mochizuki (Suita, Japan)

    Objective: The purpose of this study is to examine the distribution of tau pathology in brain regions of patients with spinocerebellar ataxia type 8 (SCA8).…
  • 2022 International Congress

    Deep brain stimulation increases descending inhibitory control in a patient with Parkinson´s disease and pain

    V. Mylius, J. Baars, G. Kägi, M. Krüger, D. de Andrade, F. Brugger (Valens, Switzerland)

    Objective: We present the first observation of deep brain stimulation (DBS) effects on spinal nociception as assessed by the nociceptive flection reflex (NFR) during DBS…
  • 2022 International Congress

    Speech markers of Presymptomatic and Prodromal Huntington’s disease

    A. Vogel, C. Chan, G. Stuart, P. Maruff, Y. Lie, J. Stout (Melbourne, Australia)

    Objective: To investigate the sensitivity of digital speech measures for detecting subtle cognitive-linguistic and fine motor features in people carrying the expanded HD gene, with…
  • 2022 International Congress

    Detection of specific antigens in immune-mediated cerebellar ataxias

    A. Kudo, H. Yaguchi, M. Abe, A. Nagai, S. Shirai, I. Takahashi-Iwata, M. Matsushima, M. Watanabe, S. Hatakeyama, I. Yabe (Sapporo, Japan)

    Objective: We aimed to clarify biomarkers and pathogenic autoantibodies in cerebellar ataxia, especially multiple system atrophy (MSA) and immune-mediated cerebellar ataxias (IMCAs), by detection of…
  • 2022 International Congress

    Short report in a dystonia cohort patients with implanted DBS systems

    B. Mukhammedaminov, A. Sufianov, A. Orlov (Tashkent, Uzbekistan)

    Objective: To review the use of bipolar and monopolar stimulation in a cohort of patients implanted DBS with Generalized Dystonia between 2012-2021 in Federal Center…
  • 2022 International Congress

    Selection of clinical doses for SBT101, an AAV9-hABCD1 vector for the treatment of adrenomyeloneuropathy

    D. Anderson, C. Maguire, C. Ng, Y. Gong, F. Eichler, S. Fourcase, C. Guilera, A. Pujol, A. Onieva, M. Leal-Julià, S. Verdés, A. Bosch, I. Dijkstra, S. Kemp, H. Park, T. Del Rio, T. Lutz, V. Vasireddy, S. Clark, K. Kozarsky (Bala Cynwyd, USA)

    Objective: To inform selection of doses of SBT101 for a first-in-human clinical study. SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate intended…
  • « Previous Page
  • 1
  • …
  • 508
  • 509
  • 510
  • 511
  • 512
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley